tiprankstipranks
Halozyme Therapeutics (HALO)
NASDAQ:HALO

Halozyme Stock Price & Analysis

662 Followers

HALO Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$31.36 - $52.98
Previous Close$39.54
Volume1.92M
Average Volume (3M)1.40M
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$209.36M
Total Debt (Recent Filing)$482.67M
P/E Ratio15.7
Beta1.38
Next EarningsNov 08, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)2.52
Shares Outstanding139,289,370
R-Squared0.28
Standard Deviation0.12
10 Day Avg. Volume1,409,630
30 Day Avg. Volume1,400,758
P/B Ratio-6.24
P/S Ratio14.82
P/CF Ratio19.40
P/FCF Ratio-6.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/EbitdaN/A
Price Target Upside33.03% Upside
Rating ConsensusStrong Buy
Alpha0.01
Number of Analyst Covering5


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

HALO FAQ

What was Halozyme’s price range in the past 12 months?
Halozyme lowest stock price was $31.36 and its highest was $52.98 in the past 12 months.
    What is Halozyme’s market cap?
    Currently, no data Available
    When is Halozyme’s upcoming earnings report date?
    Halozyme’s upcoming earnings report date is Nov 08, 2022 which is in 38 days.
      How were Halozyme’s earnings last quarter?
      Halozyme released its earnings results on Aug 09, 2022. The company reported $0.16 earnings per share for the quarter, missing the consensus estimate of $0.47 by -$0.31.
        Is Halozyme overvalued?
        According to Wall Street analysts Halozyme’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Halozyme pay dividends?
          Halozyme does not currently pay dividends.
          What is Halozyme’s EPS estimate?
          Halozyme’s EPS estimate is $0.32.
            How many shares outstanding does Halozyme have?
            Halozyme has 137,779,370 shares outstanding.
              What happened to Halozyme’s price movement after its last earnings report?
              Halozyme reported an EPS of $0.16 in its last earnings report, missing expectations of $0.47. Following the earnings report the stock price went up 1.777%.
                Which hedge fund is a major shareholder of Halozyme?
                Among the largest hedge funds holding Halozyme’s share is Driehaus Capital Management LLC. It holds Halozyme’s shares valued at 56M.

                  ---

                  Halozyme Stock Analysis

                  Smart ScoreOutperform
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10
                  8
                  The Halozyme stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Halozyme Therapeutics

                  Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

                  ---
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  AbbVie
                  Amgen
                  Gilead Sciences
                  Moderna
                  Vertex Pharmaceuticals

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis